Scandinavian ChemoTech
2.04
SEK
-0.49 %
Less than 1K followers
CMOTEC B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-0.49%
+37.84%
+65.85%
+13.97%
+16.57%
-11.17%
-81.47%
-81.7%
-94.58%
Scandinavian ChemoTech is a research and development company that has developed the technology Tumor-Specific Electroporation - TSE ™ for the treatment of various cancers. The technology means that electronic pulses are sent to the treated area and the membranes of the tumor cells are opened to reach their DNA. In addition to its operations in Sweden, the company is also active in Southeast Asia and India. Scandinavian ChemoTech was founded in 2015 and is headquartered in Lund.
Read moreMarket cap
47.62M SEK
Turnover
4.52K SEK
Revenue
6.57M
EBIT %
-194.82 %
P/E
-
Dividend yield-%
-
Financial calendar
12/8
2025
Interim report Q2'25
4/11
2025
Interim report Q3'25
3/3
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
Redeye: Scandinavian ChemoTech - Momentum continues
Scandinavian ChemoTech AB (publ) publishes Interim Report Q1 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools